NA
AMRX icon

Neuburgh Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History

Neuburgh Advisers’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-7,502
Closed -$123K – 888
2018
Q2 		$123K Buy
+7,502
New +$132K ﹤0.01% 756

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Neuburgh Advisers's AMRX Position: Q3 2018 in Review

Neuburgh Advisers sold out of Amneal Pharmaceuticals (AMRX) in Q3 2018, closing a stake of 7,502 shares — an estimated $123K sold.

Neuburgh Advisers first reported a position in AMRX in Q2 2018 and held it in 1 quarter. The position peaked at $123K in Q2 2018. 167 funds tracked by Wall St. Rank hold AMRX as of Q3 2018.

  • Neuburgh Advisers reported no remaining Amneal Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Neuburgh Advisers sold 7,502 Amneal Pharmaceuticals shares in Q3 2018, an estimated $123K.
  • Neuburgh Advisers first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Neuburgh Advisers's Amneal Pharmaceuticals position peaked at $123K in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2018.

Based on Neuburgh Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.